Samsung BioLogics signs a contract with STCube
Samsung BioLogics said Tuesday that it has signed a contract development service agreement for STCube’s anticancer drug candidate.Under the agreement, Samsung BioLogics will lead cell line development, process development and the manufacturing of the STT-033 antibody for non-clinical and clinical studies. STCube said that the STT-033 antibody, developed from STCube’s research center in Maryland, was found to have better anticancer effects than conventional PD-1/PD-L1 therapies and has been a subject of a material transfer agreement with a multinational pharmaceutical company.
STCube is a Korean biopharmaceutical company focused on developing cancer therapies. The company plans to submit an investigational new drug application for the STT-033 antibody next year, for use as a monotherapy and combination therapy with clinical trials planned at medical institutions in the United States.
By Ko Jun-tae
More in Industry
No dial tone for 2G services on LG U+ starting in June
Ironing out an air corridor took decades
Kia reinvents itself, promising 'movement that inspires'
Hanwha Energy teams up with France's Total in U.S.
Scatter Lab investigated, but not for odd messages
with the Korea JoongAng Daily
To write comments, please log in to one of the accounts.
Standards Board Policy (0/250자)